Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

RedHill Biopharma (RDHL) Gross Margin (2016 - 2023)

RedHill Biopharma has reported Gross Margin over the past 9 years, most recently at 55.12% for Q2 2023.

  • Quarterly Gross Margin rose 415.0% to 55.12% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 42.74% through Jun 2023, up 111.0% year-over-year, with the annual reading at 1927.62% for FY2025, 186732.0% up from the prior year.
  • Gross Margin was 55.12% for Q2 2023 at RedHill Biopharma, roughly flat from 55.21% in the prior quarter.
  • Over five years, Gross Margin peaked at 75.99% in Q1 2019 and troughed at 62.41% in Q1 2020.
  • The 5-year median for Gross Margin is 50.7% (2020), against an average of 43.77%.
  • Year-over-year, Gross Margin tumbled -13840bps in 2020 and then soared 11257bps in 2021.
  • A 5-year view of Gross Margin shows it stood at 50.44% in 2019, then decreased by 0bps to 50.37% in 2020, then tumbled by -75bps to 12.4% in 2021, then soared by 165bps to 32.82% in 2022, then soared by 68bps to 55.12% in 2023.
  • Per Business Quant, the three most recent readings for RDHL's Gross Margin are 55.12% (Q2 2023), 55.21% (Q1 2023), and 32.82% (Q4 2022).